Results from a Phase III registrational study suggest that ecopipam has potential as a first-in-class dopamine-1 receptor ...

Wake Forest University School of Medicine and Atrium Health Wake Forest Baptist Medical Center have been recognized by the ...

The Phase III DIAMOND trial met both its primary and secondary endpoints of reducing tics in both children and adult patients ...

Ecopipam showed statistical significance in treating Tourette syndrome versus a placebo for both its primary efficacy ...

In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...

Emalex Biosciences’ dopamine blocker led to fewer patients with Tourette syndrome relapsing in a phase 3 trial, setting the ...

Emalex Biosciences met primary and secondary endpoints in its Phase 3 registrational trial of ecopipam for patients with ...

Baylen Out Loud star Baylen Dupree has considered undergoing deep brain stimulation as a treatment for her symptoms of ...

Chicago, USA-based Emalex Biosciences announced positive top-line data from its Phase III registrational study of ecopipam, a ...

TikToker Baylen Dupree, who shares her life with Tourette Syndrome on social media, announced her engagement to Colin Dooley ...

During the double-blind withdrawal period, 41.9% of ecopipam-treated patients relapsed compared with 68.1% of placebo-treated patients. Topline data were announced from a phase 3 trial evaluating ...